Skip to content
10-Q

Quarterly Report

Akcea Therapeutics, Inc.

0001564590-20-021896

← back to feed
Filed
May 6, 2020 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2020 · Apr 29, 2020 101.51M sh
Capex Q1 2020 · Mar 31, 2020 $209K
Capex Q1 2020 · Mar 31, 2019 $1.03M
Operating Cash Flow Q1 2020 · Mar 31, 2020 −$44.11M
Operating Cash Flow Q1 2020 · Mar 31, 2019 $78.59M
Cash And Equivalents Q1 2020 · Mar 31, 2020 $163.32M
Cash And Equivalents Q1 2020 · Dec 31, 2019 $306.87M
Cash And Equivalents Q1 2020 · Mar 31, 2019 $201.03M
Stockholders Equity Q1 2020 · Mar 31, 2020 $509.69M
Stockholders Equity Q1 2020 · Dec 31, 2019 $543M
Stockholders Equity Q1 2020 · Mar 31, 2019 $388.86M
Stockholders Equity Q1 2020 · Dec 31, 2018 $276.72M
Current Liabilities Q1 2020 · Mar 31, 2020 $36.33M
Current Liabilities Q1 2020 · Dec 31, 2019 $42M
Total Liabilities Q1 2020 · Mar 31, 2020 $50.23M
Total Liabilities Q1 2020 · Dec 31, 2019 $56.25M
Current Assets Q1 2020 · Mar 31, 2020 $458.94M
Current Assets Q1 2020 · Dec 31, 2019 $496.91M
Total Assets Q1 2020 · Mar 31, 2020 $559.92M
Total Assets Q1 2020 · Dec 31, 2019 $599.25M
Sga Expense Q1 2020 · Mar 31, 2020 $46.25M
Sga Expense Q1 2020 · Mar 31, 2019 $44.6M
Net Income Q1 2020 · Mar 31, 2020 −$42.85M
Net Income Q1 2020 · Mar 31, 2019 $27.19M
Operating Income Q1 2020 · Mar 31, 2020 −$45.26M
Operating Income Q1 2020 · Mar 31, 2019 $26.21M
Revenue Q1 2020 · Mar 31, 2020 $16.07M
Revenue Q1 2020 · Mar 31, 2019 $163.82M
Shares Diluted Q1 2020 · Mar 31, 2019 94.13M sh